Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: Comparative plasma kinetics in non-clinical species

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 4, 2009, Pages 691-706

  Haznedar, Joshua Ö ^a   Patyna, Shem ^b   Bello, Carlo L ^b   Peng, Geoffrey W ^b   Speed, William ^c   Yu, Xiaoming ^d   Zhang, Qingling ^e   Sukbuntherng, Juthamas ^f   Sweeny, David J ^g   Antonian, Lida ^e   Wu, Ellen Y ^b  

^a Roche   (United States)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d BioDuro LLC   (China)

^e Genelabs Incorporated   (United States)

^f XenoPort Inc   (United States)

^g RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

Disposition; Nonclinical; Pharmacokinetics; SU12662; Sunitinib

Indexed keywords

DRUG METABOLITE; SU 12662; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; FECES; FEMALE; KINETICS; LIQUID CHROMATOGRAPHY; MALE; MONKEY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; WHOLE BODY AUTORADIOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; INDOLES; MACACA FASCICULARIS; MALE; MICE; PROTEIN KINASE INHIBITORS; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES; TANDEM MASS SPECTROMETRY;

EID: 68149137164     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0917-1     Document Type: Article

References (20)

1. TJ Abrams LB Lee LJ Murray NK Pryer JM Cherrington 2003 SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2 471 478
2. DB Mendel AD Laird X Xin SG Louie JG Christensen G Li RE Schreck TJ Abrams TJ Ngai LB Lee LJ Murray J Carver E Chan KG Moss JO Haznedar J Sukbuntherng RA Blake L Sun C Tang T Miller S Shirazian G McMahon JM Cherrington 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 327 337 (Pubitemid 36109749)
3. LJ Murray TJ Abrams KR Long TJ Ngai LM Olson W Hong PK Keast JA Brassard AM O'Farrell JM Cherrington NK Pryer 2003 SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model Clin Exp Metastasis 20 757 766
4. AM O'Farrell TJ Abrams HA Yuen TJ Ngai SG Louie KW Yee LM Wong W Hong LB Lee A Town BD Smolich WC Manning LJ Murray MC Heinrich JM Cherrington 2003 SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 3597 3605
5. JR Brahmer R Govindan S Novello R Rosell CP Belani JN Atkins HH Gillenwater L Tye R Chao MA Socinski 2007 Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study Proc Am Soc Clin Oncol 25 7542
6. Kulke MH, Lenz H-J, Meropol NJ, Posey J, Picus J, Ryan DP, Bergsland E, Stuart K, Baum CM, Fuchs CS (2005) Results of a phase II study with sunitinib malate (SU11248) in patients (pts) with advanced neuroendocrine tumors (NETS) (oral presentation). In: The 13th European cancer conference (ECCO 13), Paris, October 30-November 3, Abstract 718
7. LB Saltz LS Rosen JL Marshall RJ Belt HI Hurwitz SG Eckhardt EK Bergsland DG Haller AC Lockhart CM Rocha Lima X Huang SE DePrimo E Chow Maneval RC Chao HJ Lenz 2007 Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy J Clin Oncol 25 4793 4799
8. HJ Burstein AD Elias HS Rugo MA Cobleigh AC Wolff PD Eisenberg M Lehman BJ Adams CL Bello SE DePrimo CM Baum KD Miller 2008 A phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 1810 1816
9. MA Socinski S Novello JR Brahmer R Rosell JM Sanchez CP Belani R Govindan JN Atkins HH Gillenwater C Palleres L Tye P Selaru RC Chao GV Scagliotti 2008 Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer J Clin Oncol 26 650 656
10. AJ Zurita ND Shore MF Kozloff CW Ryan TM Beer EC Maneval I Chen CJ Logothetis 2007 Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPCa) Proc Am Soc Clin Oncol 25 5134
11. ® (sunitinib malate) capsules, oral. Prescribing information (revised: May 2008). http://www.sutent.com
12. C Washington M Eli C Bello L Schaaf E Polasek LH Tan P Scigalla N Sarapa 2003 The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics (PK) in Caucasian and Asian healthy subjects Proc Am Soc Clin Oncol 22 138 (Abstract 553)
13. C Bello B Houk L Sherman S Misbah N Sarapa J Smeraglia X Haung 2005 Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers Proc Am Soc Clin Oncol 23 3078
14. Bello C, Peng G, Patyna S, Poole W, Smeraglia J, Sherman L, Garrett M, Klamerus K (2007) A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib (SU11248) in healthy male subjects (abstract). In: American association for cancer research annual meeting, Los Angeles, April 14-18, Abstract LB-354
15. CL Bello L Sherman J Zhou L Verkh J Smeraglia J Mount KJ Klamerus 2006 Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects Anticancer Drugs 17 353 358
16. Khosravan R, Toh M, LaFargue J, Ni G, Bello C (2008) Sunitinib pharmacokinetic (PK) and safety data in subjects with renal impairment and on hemodialysis. J Clin Oncol 26 (Abstract 2578)
17. S Patyna JK Heward W Evering 2006 Non-clinical safety evaluation of sunitinib, a novel multitargeted tyrosine kinase inhibitor Tox Path 35 179 197 (Abstract 42)
18. A Mahnke D Strotkamp PH Roos WG Hanstein GG Chabot P Nef 1997 Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver Arch Biochem Biophys 337 62 68
19. Patyna S, Peng G (2006) Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer 4:21 (Abstract 56)
20. PA Zane SD Brindle DO Gause AJ O'Buck PR Raghavan SL Tripp 1990 Physicochemical factors associated with binding and retention of compounds in ocular melanin of rats: correlations using data from whole-body autoradiography and molecular modeling for multiple linear regression analyses Pharm Res 7 935 941